Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI

Tropical Medicine and International Health

Volumn 4, Issue 5, 1999, Pages 377-382

  Schellenberg, D M ^a,b   Acosta, C J ^a,b   Galindo, C M ^a,b   Kahigwa, E ^c   Urassa, H ^b   Masanja, H ^b   Aponte, J J ^a   Armstrong Schellenberg, J R M ^b,d   Fraser Hurt, N ^b,d   Lwilla, F ^e   Menendez, C ^a   Mshinda, H ^b   Tanner, M ^d   Alonso, P L ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c S Francis Designated Dist Hospital   (Tanzania)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e Hospital Clinic ^*

Author keywords

Africa; EPI; Infant; Malaria vaccine; P. falciparum; Randomized controlled trial; Safety; SPf66; Trial

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MALARIA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE;

CHILD HEALTH; DISEASE CONTROL; MALARIA; VACCINATION;

AFRICA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SAFETY; ERYTHEMA; FEVER; FOLLOW UP; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; PLASMODIUM FALCIPARUM; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALARIA; MALARIA VACCINES; MALE; POPULATION SURVEILLANCE; PROGRAM EVALUATION; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TANZANIA; VACCINES, SYNTHETIC;

TANZANIA;

EID: 0033018971     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.1999.00424.x     Document Type: Article

References (22)

1. Alonso PL, Smith T, Schellenberg JR et al. (1994) Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344, 1175-1181.
2. Acosta CJ, Galindo CM, Schellenberg D et al. (1999) Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Tropical Medicine and International Health 4, 368-376.
3. Amador R, Moreno A, Murillo LA et al. (1992a) Safety and immunogenicity of the synthetic malaria vaccine SPF66 in a large field trial. Journal of Infectious Disease 166, 1-6.
4. Amador R, Moreno A, Valero V et al. (1992b) The first field trials of the chemically synthesized malaria vaccine SPF66: safety, immunogenicity and protectivity. Vaccine 10, 179-184.
5. Basch PF (1994) Vaccines and World Health: Science, Policy and Practice, Oxford University Press, Oxford.
6. Benson P (1963) Vaccination in infancy with oral poliomyelitis vaccine and diphtheria, tetanus vaccine. British Medical Journal i, 641-643.
7. Galazka A (1990) Simultaneous administration of vaccines. In 18° Forum internacional sobre associaçao de vacinas. Fundaçao Oswaldo Cruz, Rio de Janeiro, Fiocruz, pp. 24-27.
8. Graves P (1997) Human malaria vaccines: In Infectious Diseases Module of the Cochrane Database Systematic Reviews. Updated 03 June 1997 (eds P Garner, H Gelband, P Olliaro & R Salinas) Available in the Cochrane Library (database on disk and CDROM). The Cochrane Collaboration; Issue 1 (4). Update Software, Oxford.
9. Keleman G (1961) Sabin vaccine and combined diphtheria-tetanus-pertussis immunisation. Lancet 1, 456-458.
10. Leach A, Drakeley CJ, D'Alessandro U et al. (1995) A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunology 17, 441-444.
11. Miller JJ & Ryan ML (1944) DTP vaccine. Journal of Paediatrics 1, 8-22.
12. Nelson WE (1996) Chapter 670. Nelson Textbook of Paediatrics. 15th edn (eds R E Behrman, R M Kliegman & A M Arvin) W.B. Saunders Company, Pennsylvania, pp. 2031-2084.
13. Patarroyo G, Franco L, Amador R et al. (1992) Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-years. Vaccine 10, 175-177.
14. Plotkin SA & Mortimer EA (1994) Vaccines. 2nd edn., W.B. Saunders Company, Pennsylvania.
15. Purves LR & de Franco SE (1995) Chemical Pathology. Handbook of Paediatrics, 4th edn (ed. HV Heese) Oxford University Press, Cape Town, pp. 130-145.
16. Sempértegui F, Estrella B, Moscoso J et al. (1994) Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12, 337-342.
17. Tanner M, de Savigny D, Mayombana C et al. (1991) Morbidity and mortality at Kilombero, Tanzania, 1982-, 1988. Disease and Mortality in Sub-Saharan Africa (eds R Feachem & C Jamieson) Oxford University Press, Oxford, pp. 286-305.
18. Valero MV, Amador R, Galindo C et al. (1993) Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341, 705-710.
19. Valero MV, Amador R, Aponte JJ et al. (1996) Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 14, 1466-1470.
20. WHO (1982) Manual of details of tests on final vaccines used in the WHO Expanded Programme of Immunisation BLG/UNDP/82.1 Rev 1 edn.
21. WHO (1996) World malaria situation in 1993. Weekly Epidemiological Records 71, 17-22.
22. World Bank (1993) World Development Report 1993: Investing in Health, Oxford University Press, Oxford.